Document:

EX-10.19.1

 Exhibit 10.19.1 

OMNIBUS AMENDMENT AGREEMENT 
 This OMNIBUS AMENDMENT AGREEMENT (this “Amendment”) is entered into as of November 8, 2012, by and among Biocept, Inc., a
California corporation (the “Company”), and The Reiss Family Survivor’s Trust UDT dated December 19, 1988 (the “Survivor’s Trust”), The Reiss Family GST Ex Marital Deduction Trust UDT
12/19/1988 (the “Marital Trust”), M. Faye Wilson, Bruce E. Gerhardt and Hale Biopharmaventures, LLC (collectively, the “Investors”). 

RECITALS 
 A. The Company and the Investors are parties to that certain Note and Warrant Purchase Agreement, dated as of January 13, 2012, as amended (the “Purchase Agreement”).

 B. Pursuant to the Purchase Agreement the Company issued to the Investors (i) a
Promissory Note, dated January 13, 2012, in the principal amount of $750,000, (ii) a Promissory Note, dated February 15, 2012, in the principal amount of $250,000, (iii) a Promissory Note, dated February 21, 2012, in the
principal amount of $20,000, (iv) a Promissory Note, dated February 28, 2012, in the principal amount of $250,000, (v) a Promissory Note, dated February 28, 2012, in the principal amount of $20,000, (vi) a Promissory Note,
dated March 12, 2012, in the principal amount of $250,000, (vii) a Promissory Note, dated March 16, 2012, in the principal amount of $50,000, (viii) a Promissory Note, dated March 26, 2012, in the principal amount of
$350,000, (ix) a Promissory Note, dated April 5, 2012, in the principal amount of $500,000, (x) a Promissory Note, dated April 18, 2012, in the principal amount of $500,000, (xi) a Promissory Note, dated May 1, 2012, in
the principal amount of $500,000, (xii) a Promissory Note, dated May 29, 2012, in the principal amount of $500,000, (xiii) a Promissory Note, dated August 7, 2012, in the principal amount of $50,000 and (xiv) a Promissory
Note, dated August 30, 2012, in the principal amount of $250,000 (collectively, the “Outstanding Notes”). 
 C. On May 31, 2012, the Maturity Date (as defined in the Outstanding Notes) set forth in the Outstanding Notes was triggered and the unpaid principal and accrued interest outstanding under the
Outstanding Notes was not paid on such Maturity Date (the “Failure to Pay Event”), and the Investors, to the extent applicable, desire to waive any event of default under (i) the Outstanding Notes, (ii) the Secured
Convertible Promissory Notes issued by the Company pursuant to that certain Note and Warrant Purchase Agreement, dated as of February 1, 2011, as amended, and (iii) the Secured Convertible Promissory Note issued pursuant to that certain
Note and Warrant Purchase Agreement, dated as of December 22, 2008, by and between the Company, the Survivor’s Trust and the Marital Trust, in each such case associated with such Failure to Pay Event (an “Event of
Default”). 
 D. The Company and the Investors desire to amend the Outstanding Notes to extend the Maturity
Date of the Outstanding Notes. 

  
 1. 

 E. Section 13 of the Outstanding Notes provides that
the Outstanding Notes may be amended, and any term of the Outstanding Notes may be waived, with the written consent of the Company and the holders of at least a majority of the then-outstanding principal amount of all promissory notes issued
pursuant to the Purchase Agreement (the “Majority Holders”).  
 F. The Company and
the Majority Holders desire to amend the Purchase Agreement to (i) provide that all Promissory Notes issued pursuant to the Purchase Agreement shall have the same Maturity Date and (ii) to provide that the Company shall be permitted to
issue up to $8,000,000 in aggregate principal amount of Promissory Notes.  
 G. Section 6.7 of the Purchase
Agreement provides that the Purchase Agreement may be amended with the written consent of the Company and the Majority Holders.  
 AGREEMENT 
 In exchange for other good and valuable
consideration, the receipt and adequacy of which is hereby acknowledged, the parties agree as follows: 
 1. Waiver of Event
of Default. The Investors hereby waive any Event of Default associated with the Failure to Pay Event. 
 2.
Amendment to Outstanding Notes. Section 5 of the Outstanding Notes is hereby amended and restated in its entirety as set forth below: 
 “5 Maturity Date. This Note and all unpaid principal and accrued interest outstanding under this Note shall be due and payable upon the earlier of (i) an Event of Default (defined below),
(ii) the closing of an equity financing following the date hereof involving the sale by the Company of its Preferred Stock in which the Company receives an aggregate of at least $15,000,000 in cumulative gross proceeds (a
“Qualifying Financing”), (iii) November 30, 2012, if, as of such date, the Company has not received a term sheet for a Qualifying Financing that is acceptable to the Company’s Board of Directors
and (iv) December 31, 2012, if, as of such date, a Qualifying Financing has not occurred (the earliest of such dates, the “Maturity Date”).” 

3. Amendment to Exhibit A of Purchase Agreement. Exhibit A of the Purchase Agreement shall be amended and restated to read in its
entirety as set forth on Exhibit A hereto. 

  
 2. 

 4. Recitals. The reference to “$5,000,000” in the “whereas”
clause contained in the recitals of the Purchase Agreement is hereby amended and restated such that it shall be “$8,000,000.” 
 5. Miscellaneous. 
 (a) This Amendment may be executed in any number
of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile or electronic signatures shall be as effective as original signatures. 

(b) Except as expressly modified by this Amendment, the Purchase Agreement and the Outstanding Notes shall remain unmodified and
in full force and effect. 
 (c) This Amendment shall be governed by and construed under the laws of the State of
California as applied to agreements among California residents, made and to be performed entirely within the State of California without giving effect to its conflicts of laws principles. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

  
 3. 

 IN WITNESS WHEREOF, the parties hereto
have executed this OMNIBUS AMENDMENT AGREEMENT as of the date set forth in the first paragraph above. 

 

			
	 COMPANY:
  

BIOCEPT, INC.
 a California corporation

		
	By:	 	/s/ William G. Kachioff
	Name:	 	William G. Kachioff
	Title:	 	CFO

 IN WITNESS WHEREOF, the
parties hereto have executed this OMNIBUS AMENDMENT AGREEMENT as of the date set forth in the first paragraph above. 

 

			
	INVESTORS:
	
	 THE REISS FAMILY GST EX MARITAL

DEDUCTION TRUST UDT 12/19/1988:

		
	By:	 	/s/ Claire K.T. Reiss
	Name:	 	Claire K.T. Reiss
	Title:	 	Trustee

  

			
	
	 THE REISS FAMILY SURVIVOR’S
TRUST
 UDT DATED DECEMBER 19, 1988:

		
	By:	 	 /s/ Claire K.T. Reiss

	Name:	 	 Claire K.T. Reiss

	Title:	 	Trustee

  

			
	M. FAYE WILSON
	
	 
	  

BRUCE E. GERHARDT

	
	 
	
	
	HALE BIOPHARMAVENTURES, LLC
		
	By:	 	/s/ David F. Hale
	Name:	 	David F. Hale
	Title:	 	Chairman & CEO

 EXHIBIT A 

FORM OF PROMISSORY NOTEEX-10.19.2

 Exhibit 10.19.2 

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE OFFERED,
SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED.

 THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THIS NOTE IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN NOTE AND
WARRANT PURCHASE AGREEMENT BY AND BETWEEN THE INVESTOR AND THE COMPANY. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY. 
 BIOCEPT, INC. 
 PROMISSORY NOTE 

 

							
	$[                ]	  		  		  	
[                    ],
2012
 San Diego, California

 FOR VALUE RECEIVED,
BIOCEPT, INC., a California corporation (the “Company”), hereby promises to pay to the order of
[                    ] (collectively, the “Investor”), the principal sum of
$[            ] (the “Loan Amount”), together with accrued and unpaid interest thereon, each due and payable on the date and in the manner set forth below.

 This Note is issued pursuant to the Note and Warrant Purchase Agreement, dated January 13, 2012, by and
among the Company and the signatories thereto (the “Purchase Agreement”). Capitalized terms used and not otherwise defined herein shall have the meanings given them in the Purchase Agreement. 

1.        Interest.    Interest shall accrue on the outstanding
principal amount hereof from the date of this Note until payment in full, which interest shall be payable at the rate of 10% per annum. Interest shall be due and payable on the Maturity Date (as defined below), and shall be calculated on the
basis of a 365-day year for the actual number of days elapsed. 

2.        Payment.    Payment shall be made in lawful money of the
United States to the Investor at the Company’s principal offices or, at the option of the Investor, at such other place in the United States as Investor shall have designated by written notice to the Company. All payments shall be applied first
to accrued interest and thereafter to principal. 
 3.        Optional
Prepayment.    The Company may prepay the principal or accrued interest outstanding under this Note at any time, without penalty, in whole or in part. 
 4.        Required Prepayment.    If, at any time prior to the Maturity Date, the Company has more than $1,000,000 of cash and cash
equivalents (such amount of cash and cash equivalents in 

 
excess of $1,000,000, the “Cash Reserves”), then the Company shall be required to utilize the “pro rata portion” of the Cash Reserves to prepay the principal or
accrued interest outstanding under this Note. The “pro rata portion” of the Cash Reserves shall be an amount equal to the product obtained by multiplying (i) the aggregate Cash Reserves by (ii) a fraction, the denominator of
which is the aggregate principal amount then-outstanding on all Notes issued pursuant to the Purchase Agreement and the numerator of which is the principal amount then-outstanding on this Note. 

5.        Maturity Date.    This Note and all unpaid principal and
accrued interest outstanding under this Note shall be due and payable upon the earlier of (i) an Event of Default (defined below), (ii) the closing of an equity financing following the date hereof involving the sale by the Company of its
Preferred Stock in which the Company receives an aggregate of at least $15,000,000 in cumulative gross proceeds (a “Qualifying Financing”), (iii) May 31, 2012, if, as of such date, the Company has not
received a term sheet for a Qualifying Financing that is acceptable to the Company’s Board of Directors and (iv) July 31, 2012, if, as of such date, a Qualifying Financing has not occurred (the earliest of such dates, the
“Maturity Date”). 
 6.        Termination of
Rights.    All rights with respect to this Note shall terminate upon a payment of the principal and accrued interest outstanding under this Note in full, whether or not this Note has been surrendered. 

7.        Default.    Each of the following events shall be an
“Event of Default” hereunder: 
 (a)      The
Company commits a material breach of the representations, warranties or covenants in the Purchase Agreement which is not cured within 5 calendar days after notice thereof from the Investor; 

(b)      The Company’s failure to pay all unpaid principal and accrued
interest outstanding under this Note on the Maturity Date; 
 (c)      The
voluntary dissolution or liquidation of the Company; 
 (d)      The
Company’s voluntary cessation of business operations; 
 (e)      The
Company’s closing of an Acquisition or Asset Transfer (each as defined in the Company’s Amended and Restated Articles of Incorporation (the “Articles”)) (except that an Acquisition or Asset Transfer shall not
include a reincorporation of the Company solely to effect a change of domicile of the Company); 

(f)      The occurrence of an event of default related to any indebtedness of the
Company which is not cured within 15 calendar days; 
 (g)      The
Company files a petition or action for relief under any bankruptcy, insolvency or moratorium law or any other law for the relief of, or relating to, debtors, now or hereafter in effect, or makes any assignment for the benefit of creditors or takes
any action in furtherance of any of the foregoing; or 

  
 2. 

 (h)      An involuntary petition is
filed against the Company (unless such petition is dismissed or discharged within 60 days) under any bankruptcy statute now or hereafter in effect, or a custodian, receiver, trustee, assignee for the benefit of creditors (or other similar official)
is appointed to take possession, custody or control of any property of the Company. 
 Upon the occurrence of an
Event of Default, all unpaid principal, accrued interest and other amounts owing hereunder shall, at the option of the Investor, and, in the case of an Event of Default pursuant to (g) or (h) above, automatically, be immediately due,
payable and collectible by the Investor pursuant to applicable law. Subject to the provisions hereof, the Investor shall have all rights and may exercise any remedies available to it under law, successively or concurrently. 

8.        No Impairment.    Except and to the extent as waived or
consented to by the Investor in accordance with Section 13 below, the Company will not, by amendment of the Articles or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of any debt or equity
securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by the Company, but will at all times in good faith assist in the carrying out of all the
provisions of this Note in order to protect the rights of Investor hereunder against impairment. 

9.        Highest Lawful Rate.    Anything herein to the contrary
notwithstanding, if during any period for which interest is computed hereunder, the amount of interest computed on the basis provided for in this Note, together with all fees, charges, and other payments or rights which are treated as interest under
applicable law, as provided for herein or in any other document executed in connection herewith, would exceed the amount of such interest computed on the basis of the Highest Lawful Rate (as defined below), the Company shall not be obligated to pay,
and the Investor shall not be entitled to charge, collect, receive, reserve, or take, interest in excess of the Highest Lawful Rate, and during any such period the interest payable hereunder shall be computed on the basis of the Highest Lawful Rate.
“Highest Lawful Rate” means the maximum non-usurious rate of interest, as in effect from time to time, which may be charged, contracted for, reserved, received, or collected by the Investor in connection with this Note under
applicable law. In accordance with this section, any amounts received in excess of the Highest Lawful Rate shall be applied towards the prepayment of principal then outstanding. 

10.        Waiver.    Subject to any other provision herein or in the
Loan Documents, the Company hereby waives demand, notice, presentment, protest and notice of dishonor. 

11.        Governing Law.    This Note shall be governed by, and
construed and enforced in accordance with, the laws of the State of California, applied to agreements between California residents, made to be performed entirely within the State of California, without giving effect to conflict of laws principles.

 12.        Successors and Assigns.    Neither this Note
nor any rights hereunder shall be transferable by the Investor without the prior written consent of the Company, except to an Affiliate of the Investor that agrees in writing to be subject to the terms of this Note to the same extent as if such
Affiliate were an original Investor hereunder. Subject to the foregoing, the provisions of this 

  
 3. 

 
Note shall inure to the benefit of and be binding on any successor to the Company and shall extend to any holder hereof. 
 13.        Amendment; Waiver.    Any term of this Note may be amended or waived with the written consent of (i) the Company and
(ii) the holders of at least a majority of the then-outstanding principal amount of all promissory notes issued pursuant to the Purchase Agreement. 
 14.        Counterparts.    This Note may be executed in two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. 
 [REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

  
 4. 

 IN WITNESS WHEREOF, the
Company has caused this PROMISSORY NOTE to be executed by its duly authorized officer as of the date first written above. 

 

			
	BIOCEPT, INC.
		
	By:	 	 

 
			
		
	Title:	 	 

 Acknowledged and Accepted: 
 [                            ]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]